SENSEX NIFTY

Trastuzumab

Feb 22, 2017 at 20:38 | Source: PTI
The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.
Jan 25, 2017 at 11:02 | Source: CNBC-TV18
Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.
Jan 12, 2017 at 09:44 | Source: Moneycontrol.com
Biocon shares touched a record high of Rs 1,049.50 on Thursday, up nearly 5 percent intraday after the US health regulator has accepted biosimilar application for its proposed cancer drug.
Jan 12, 2017 at 08:56 | Source: PTI
The proposed biosimilar trastuzumab is one of the six biologic products co-developed by Mylan and Biocon for the global marketplace, the two companies said in a statement.
Jan 12, 2017 at 08:43 | Source: CNBC-TV18
Following US president-elect Donald Trumps explosive speech last night where he lambasted the domestic pharma companies for outsourcing work, pharma stocks are likely to be in limelight today.
Jan 12, 2017 at 08:21 | Source: Moneycontrol.com
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylans biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
Dec 27, 2016 at 15:41 | Source: Moneycontrol.com
This study was the last major step of a multiple-phased programme to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.
Dec 22, 2016 at 12:02 | Source: CNBC-TV18
Biocon is among the companies that gave a good performance in 2016 and the stock surged 80 percent this year. Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of the company, said the company has gained traction in many emerging markets with its biosimilars.
Dec 06, 2016 at 12:52 | Source: CNBC-TV18
Speaking to CNBC-TV18, Kiran Mazumdar Shaw, CMD of Biocon said huge opportunities exist for Biocon in the US biosimilars market.
Aug 26, 2016 at 09:13 | Source: CNBC-TV18
The European Medicines Agency (EMA) has accepted to review Mylan and Biocons application for a biosimilar called Trastuzumab, used for certain breast and gastric cancers.
Messages on Trastuzumab »

biomagic

New Member

19 Followers

Biocon  

as per Biocon MD- We have 10 biosimilars in the pipeline and their combined market opportunity is $60 billion. The four most advanced biosimilar programs namely, Insulin Glargine, Trastuzumab, Pegfilgrastim and Adalimumab, have an addressable market size of $30 billion globally at 2015 reference

10.22 PM Mar 24th

sawdhan

New Member

5 Followers

Biocon  

us patent for trastuzumab is valid up to 2019 ): eu & row only post approval... how 55-65 eps

1.35 PM Mar 21st

savera_patn
a

Platinum Member

40 Followers

Biocon  

Remarkable deal struck by Mylan with patent holder Roche. They will instantly launch Trastuzumab in Europe/US post approval whereas others will have to do patent dance in US .

8.41 PM Mar 14th

koppik

Gold Member

11 Followers

Biocon  

Quoting the release: "In addition to eliminating any legal uncertainty over the launch of Mylan`s trastuzumab, the settlement eliminates further patent litigation expenses associated with Genentech and Roche." "Following this settlement and the recent acceptance of Mylan`s application for its

9.06 PM Mar 13th

pennystktra
der

New Member

2 Followers

Biocon  

The legal battle involving drugmaker Roche s breast cancer drug Trastuzumab took a significant turn on Friday with the Delhi High Court allowing drugmakers Biocon and Mylan to sell their version of the biosimilar drug for three treatment indications.

2.03 PM Mar 6th

andyin

New Member

6 Followers

Biocon  

Market is reacting to Roche clearing Perjata study which may have impact on Trastuzumab sales as Perjata has superior survival rates. But the big question is how many people can afford it. So negligible to nil impact to in most of the markets. In US and Europe may be marginal impact. Anyway all

3.50 PM Mar 2nd

News Flash

Platinum Member

1428 Followers

Just Posted  

Sources On Biocon CNBC-TV18 Exclusive : EMA Reviews Filings For Pegfilgrastim, Trastuzumab & Insulin Glargine

11.15 AM Mar 2nd

News Flash

Platinum Member

1428 Followers

Just Posted  

CNBC-TV18 ALERT : Biocon's Goal Date For Trastuzumab U/ Biosimilar User Fee Act Is Sep 3, 2017

11.15 AM Mar 2nd

News Flash

Platinum Member

1428 Followers

Just Posted  

CNBC-TV18 ALERT : Trastuzumab Is Used In Treatment Of Certain Types Of Breast Cancer

11.15 AM Mar 2nd

News Flash

Platinum Member

1428 Followers

Just Posted  

CNBC-TV18 ALERT : US FDA Accepted BLA For Trastuzumab By Biocon & Mylan In January

11.15 AM Mar 2nd

Follow us on
Available On